nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—Clenbuterol—NGF—Parkinson's disease	0.0513	0.352	CrCbGaD
Salbutamol—Isoprenaline—ADRBK1—Parkinson's disease	0.0232	0.159	CrCbGaD
Salbutamol—Epinephrine—ADRBK1—Parkinson's disease	0.0195	0.134	CrCbGaD
Salbutamol—Norepinephrine—SLC18A2—Parkinson's disease	0.0119	0.082	CrCbGaD
Salbutamol—Phenylephrine—MAOA—Parkinson's disease	0.0112	0.0771	CrCbGaD
Salbutamol—Clenbuterol—TNF—Parkinson's disease	0.00994	0.0683	CrCbGaD
Salbutamol—Carteolol—CYP2D6—Parkinson's disease	0.00654	0.0449	CrCbGaD
Salbutamol—Epinephrine—TNF—Parkinson's disease	0.00418	0.0287	CrCbGaD
Salbutamol—Nadolol—ABCB1—Parkinson's disease	0.00416	0.0286	CrCbGaD
Salbutamol—Norepinephrine—DRD2—Parkinson's disease	0.00368	0.0253	CrCbGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—PDYN—Parkinson's disease	0.00319	0.00374	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—PDYN—Parkinson's disease	0.00312	0.00365	CbGpPWpGaD
Salbutamol—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—Parkinson's disease	0.003	0.00351	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—ADORA2A—Parkinson's disease	0.00294	0.00345	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—ADORA2A—Parkinson's disease	0.00288	0.00337	CbGpPWpGaD
Salbutamol—CYP3A4—Tryptophan metabolism—CYP2E1—Parkinson's disease	0.00287	0.00336	CbGpPWpGaD
Salbutamol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—Parkinson's disease	0.00285	0.00334	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—GRM4—Parkinson's disease	0.0028	0.00328	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—MAOB—Parkinson's disease	0.00277	0.00324	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—GRM4—Parkinson's disease	0.00274	0.00321	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—PENK—Parkinson's disease	0.00266	0.00311	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—PENK—Parkinson's disease	0.0026	0.00304	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR1A—Parkinson's disease	0.00255	0.00299	CbGpPWpGaD
Salbutamol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2D6—Parkinson's disease	0.00254	0.00297	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADORA2A—Parkinson's disease	0.00252	0.00295	CbGpPWpGaD
Salbutamol—CYP3A4—Oxidation by Cytochrome P450—CYP2D6—Parkinson's disease	0.00251	0.00293	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR1A—Parkinson's disease	0.0025	0.00292	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ADORA2A—Parkinson's disease	0.00247	0.00289	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD1—Parkinson's disease	0.00247	0.00289	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—PDYN—Parkinson's disease	0.00243	0.00284	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD1—Parkinson's disease	0.00241	0.00282	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD3—Parkinson's disease	0.00239	0.0028	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—PDYN—Parkinson's disease	0.00238	0.00278	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD3—Parkinson's disease	0.00234	0.00274	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—DGKQ—Parkinson's disease	0.00233	0.00273	CbGpPWpGaD
Salbutamol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—Parkinson's disease	0.00232	0.00272	CbGpPWpGaD
Salbutamol—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—Parkinson's disease	0.00229	0.00268	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—DGKQ—Parkinson's disease	0.00228	0.00267	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—GRM5—Parkinson's disease	0.00226	0.00264	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—GRM5—Parkinson's disease	0.00221	0.00259	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR1A—Parkinson's disease	0.00219	0.00256	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR7—Parkinson's disease	0.00216	0.00253	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD2—Parkinson's disease	0.00216	0.00253	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—TAC1—Parkinson's disease	0.00216	0.00252	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR1A—Parkinson's disease	0.00214	0.00251	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—GPR37—Parkinson's disease	0.00212	0.00248	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—DGKQ—Parkinson's disease	0.00212	0.00248	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR7—Parkinson's disease	0.00211	0.00247	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—Parkinson's disease	0.00211	0.00247	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD1—Parkinson's disease	0.00211	0.00247	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—TAC1—Parkinson's disease	0.00211	0.00247	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—GPR37—Parkinson's disease	0.00207	0.00242	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—DGKQ—Parkinson's disease	0.00207	0.00242	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD1—Parkinson's disease	0.00207	0.00242	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—CYP2D6—Parkinson's disease	0.00206	0.00241	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD3—Parkinson's disease	0.00205	0.0024	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD3—Parkinson's disease	0.002	0.00234	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PPP1R1B—Parkinson's disease	0.00194	0.00227	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—ADORA2A—Parkinson's disease	0.00192	0.00225	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PPP1R1B—Parkinson's disease	0.00189	0.00222	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—Parkinson's disease	0.00188	0.0022	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—ADORA2A—Parkinson's disease	0.00188	0.0022	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD2—Parkinson's disease	0.00185	0.00217	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR7—Parkinson's disease	0.00185	0.00217	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR7—Parkinson's disease	0.00181	0.00212	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—Parkinson's disease	0.00181	0.00212	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—GRK5—Parkinson's disease	0.00177	0.00207	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—GRK5—Parkinson's disease	0.00173	0.00202	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—HTR1A—Parkinson's disease	0.00167	0.00195	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—GSTA4—Parkinson's disease	0.00165	0.00193	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—TAC1—Parkinson's disease	0.00164	0.00192	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—HTR1A—Parkinson's disease	0.00163	0.00191	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—GSTA4—Parkinson's disease	0.00163	0.0019	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—DRD1—Parkinson's disease	0.00161	0.00188	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—TAC1—Parkinson's disease	0.00161	0.00188	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—GRK5—Parkinson's disease	0.0016	0.00188	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—GRM4—Parkinson's disease	0.00158	0.00185	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—DRD1—Parkinson's disease	0.00157	0.00184	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—GRK5—Parkinson's disease	0.00157	0.00184	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—DRD3—Parkinson's disease	0.00156	0.00182	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—GRM4—Parkinson's disease	0.00155	0.00181	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—Parkinson's disease	0.00155	0.00181	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—DRD3—Parkinson's disease	0.00153	0.00178	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—Parkinson's disease	0.00151	0.00177	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—VPS35—Parkinson's disease	0.00151	0.00177	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PENK—Parkinson's disease	0.0015	0.00176	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—EDN1—Parkinson's disease	0.00148	0.00173	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—Parkinson's disease	0.00148	0.00173	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—VPS35—Parkinson's disease	0.00148	0.00173	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—MAOB—Parkinson's disease	0.00147	0.00172	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PENK—Parkinson's disease	0.00147	0.00172	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—EDN1—Parkinson's disease	0.00145	0.0017	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—GRM4—Parkinson's disease	0.00144	0.00168	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—HTR7—Parkinson's disease	0.00141	0.00165	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—DRD2—Parkinson's disease	0.00141	0.00165	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—GRM4—Parkinson's disease	0.00141	0.00165	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—DRD2—Parkinson's disease	0.00138	0.00161	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—HTR7—Parkinson's disease	0.00138	0.00161	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PDYN—Parkinson's disease	0.00137	0.00161	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PENK—Parkinson's disease	0.00136	0.0016	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PDYN—Parkinson's disease	0.00134	0.00157	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PENK—Parkinson's disease	0.00133	0.00156	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Parkinson's disease	0.0013	0.00152	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—GRM5—Parkinson's disease	0.00128	0.00149	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Parkinson's disease	0.00127	0.00148	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GPR37—Parkinson's disease	0.00125	0.00146	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—DGKQ—Parkinson's disease	0.00125	0.00146	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—GRM5—Parkinson's disease	0.00125	0.00146	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PDYN—Parkinson's disease	0.00125	0.00146	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GPR37—Parkinson's disease	0.00122	0.00143	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—DGKQ—Parkinson's disease	0.00122	0.00143	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PDYN—Parkinson's disease	0.00122	0.00143	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—GRM5—Parkinson's disease	0.00116	0.00136	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PPP1R1B—Parkinson's disease	0.00114	0.00134	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—GRM5—Parkinson's disease	0.00113	0.00133	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—EDN1—Parkinson's disease	0.00113	0.00132	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PPP1R1B—Parkinson's disease	0.00112	0.00131	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—EDN1—Parkinson's disease	0.0011	0.00129	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—CYP2D6—Parkinson's disease	0.00109	0.00128	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—ADORA2A—Parkinson's disease	0.00109	0.00127	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—CYP2D6—Parkinson's disease	0.00108	0.00126	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—ADORA2A—Parkinson's disease	0.00106	0.00124	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—CYP2E1—Parkinson's disease	0.001	0.00117	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RIT2—Parkinson's disease	0.000999	0.00117	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—HTR2A—Parkinson's disease	0.000988	0.00116	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—CYP2E1—Parkinson's disease	0.000986	0.00115	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—ADORA2A—Parkinson's disease	0.000986	0.00115	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RIT2—Parkinson's disease	0.000978	0.00114	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—HTR2A—Parkinson's disease	0.000966	0.00113	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—ADORA2A—Parkinson's disease	0.000964	0.00113	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GRK5—Parkinson's disease	0.000947	0.00111	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—HTR1A—Parkinson's disease	0.000942	0.0011	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—TAC1—Parkinson's disease	0.000928	0.00109	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GRK5—Parkinson's disease	0.000927	0.00108	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—HTR1A—Parkinson's disease	0.000921	0.00108	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—DRD1—Parkinson's disease	0.00091	0.00106	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—TAC1—Parkinson's disease	0.000907	0.00106	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—DRD1—Parkinson's disease	0.00089	0.00104	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—DRD3—Parkinson's disease	0.000881	0.00103	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—DRD3—Parkinson's disease	0.000862	0.00101	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HTR1A—Parkinson's disease	0.000855	0.001	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GRM4—Parkinson's disease	0.00085	0.000994	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—TAC1—Parkinson's disease	0.000842	0.000986	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HTR1A—Parkinson's disease	0.000837	0.000979	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GRM4—Parkinson's disease	0.000831	0.000973	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—COMT—Parkinson's disease	0.000828	0.00097	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—DRD1—Parkinson's disease	0.000826	0.000967	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—GSTP1—Parkinson's disease	0.000825	0.000965	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—TAC1—Parkinson's disease	0.000824	0.000964	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—ADRBK1—Parkinson's disease	0.000823	0.000963	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—MAOA—Parkinson's disease	0.000823	0.000963	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—COMT—Parkinson's disease	0.000817	0.000956	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—GSTP1—Parkinson's disease	0.000813	0.000952	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—DRD1—Parkinson's disease	0.000808	0.000946	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAG—Parkinson's disease	0.000806	0.000943	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PENK—Parkinson's disease	0.000806	0.000943	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—ADRBK1—Parkinson's disease	0.000805	0.000942	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—DRD3—Parkinson's disease	0.0008	0.000936	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—DRD2—Parkinson's disease	0.000797	0.000933	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—HTR7—Parkinson's disease	0.000797	0.000933	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAG—Parkinson's disease	0.000788	0.000922	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PENK—Parkinson's disease	0.000788	0.000922	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—DRD3—Parkinson's disease	0.000783	0.000916	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—DRD2—Parkinson's disease	0.000779	0.000912	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—HTR7—Parkinson's disease	0.000779	0.000912	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—GSTM1—Parkinson's disease	0.000758	0.000887	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—GSTM1—Parkinson's disease	0.000747	0.000875	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—ADRBK1—Parkinson's disease	0.000747	0.000874	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PDYN—Parkinson's disease	0.000737	0.000862	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—ADRBK1—Parkinson's disease	0.000731	0.000855	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—DRD2—Parkinson's disease	0.000724	0.000847	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HTR7—Parkinson's disease	0.000724	0.000847	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PDYN—Parkinson's disease	0.000721	0.000843	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—DRD2—Parkinson's disease	0.000708	0.000828	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HTR7—Parkinson's disease	0.000708	0.000828	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GFAP—Parkinson's disease	0.000693	0.000811	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GRM5—Parkinson's disease	0.000685	0.000802	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GFAP—Parkinson's disease	0.000678	0.000793	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GRM5—Parkinson's disease	0.00067	0.000784	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—EDN1—Parkinson's disease	0.000638	0.000747	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—EDN1—Parkinson's disease	0.000624	0.00073	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGF20—Parkinson's disease	0.000601	0.000703	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGF20—Parkinson's disease	0.000588	0.000688	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADORA2A—Parkinson's disease	0.000582	0.000682	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—EDN1—Parkinson's disease	0.000579	0.000678	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ADORA2A—Parkinson's disease	0.00057	0.000667	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—EDN1—Parkinson's disease	0.000567	0.000663	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—HTR2A—Parkinson's disease	0.000558	0.000653	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—HTR2A—Parkinson's disease	0.000546	0.000639	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—INSR—Parkinson's disease	0.000537	0.000629	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ND3—Parkinson's disease	0.000537	0.000629	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MCCC1—Parkinson's disease	0.000537	0.000629	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—INSR—Parkinson's disease	0.000526	0.000615	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGB—Parkinson's disease	0.000508	0.000595	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HTR2A—Parkinson's disease	0.000507	0.000593	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HTR1A—Parkinson's disease	0.000505	0.000591	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—OMD—Parkinson's disease	0.000505	0.000591	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TALDO1—Parkinson's disease	0.000505	0.000591	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TAC1—Parkinson's disease	0.000498	0.000582	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGB—Parkinson's disease	0.000497	0.000582	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HTR2A—Parkinson's disease	0.000496	0.00058	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HTR1A—Parkinson's disease	0.000494	0.000579	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—DRD1—Parkinson's disease	0.000488	0.000571	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TAC1—Parkinson's disease	0.000487	0.00057	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	0.000479	0.00056	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—DRD1—Parkinson's disease	0.000477	0.000559	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—DRD3—Parkinson's disease	0.000473	0.000553	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—DRD3—Parkinson's disease	0.000462	0.000541	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GCH1—Parkinson's disease	0.000457	0.000535	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADRBK1—Parkinson's disease	0.000441	0.000517	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ADRBK1—Parkinson's disease	0.000432	0.000505	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HTR7—Parkinson's disease	0.000427	0.0005	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—DRD2—Parkinson's disease	0.000427	0.0005	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HTR7—Parkinson's disease	0.000418	0.000489	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—DRD2—Parkinson's disease	0.000418	0.000489	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—DBH—Parkinson's disease	0.000407	0.000476	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—FBP1—Parkinson's disease	0.000407	0.000476	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GBA—Parkinson's disease	0.000407	0.000476	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IGF2—Parkinson's disease	0.000358	0.000419	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IGF2—Parkinson's disease	0.00035	0.00041	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IGF1R—Parkinson's disease	0.000346	0.000405	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EDN1—Parkinson's disease	0.000342	0.000401	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IGF1R—Parkinson's disease	0.000339	0.000397	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EDN1—Parkinson's disease	0.000335	0.000392	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NGF—Parkinson's disease	0.000314	0.000368	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NGF—Parkinson's disease	0.000308	0.00036	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HTR2A—Parkinson's disease	0.000299	0.00035	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—DDC—Parkinson's disease	0.000299	0.00035	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HTR2A—Parkinson's disease	0.000293	0.000343	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTA4—Parkinson's disease	0.000282	0.00033	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APOE—Parkinson's disease	0.000278	0.000326	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APOE—Parkinson's disease	0.000272	0.000319	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	0.000254	0.000297	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MAOB—Parkinson's disease	0.000252	0.000294	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—INS—Parkinson's disease	0.000238	0.000278	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—INS—Parkinson's disease	0.000233	0.000272	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	0.000187	0.000219	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CTGF—Parkinson's disease	0.000183	0.000215	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CASP3—Parkinson's disease	0.000177	0.000207	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL6—Parkinson's disease	0.000176	0.000206	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CASP3—Parkinson's disease	0.000173	0.000203	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL6—Parkinson's disease	0.000172	0.000201	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	0.000171	0.0002	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NQO1—Parkinson's disease	0.000169	0.000198	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TH—Parkinson's disease	0.000167	0.000195	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAPK8—Parkinson's disease	0.000163	0.00019	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYCS—Parkinson's disease	0.00016	0.000187	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAPK8—Parkinson's disease	0.000159	0.000186	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—COMT—Parkinson's disease	0.000142	0.000166	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTP1—Parkinson's disease	0.000141	0.000165	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MAOA—Parkinson's disease	0.000141	0.000165	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HMOX1—Parkinson's disease	0.000139	0.000163	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCB1—Parkinson's disease	0.000133	0.000156	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTM1—Parkinson's disease	0.00013	0.000152	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GPX1—Parkinson's disease	0.000124	0.000145	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MTHFR—Parkinson's disease	0.000115	0.000134	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APOE—Parkinson's disease	0.000107	0.000125	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL6—Parkinson's disease	0.000104	0.000122	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL6—Parkinson's disease	0.000102	0.000119	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—INS—Parkinson's disease	9.11e-05	0.000107	CbGpPWpGaD
